Long Term Oxygen Therapy in Patients With Interstitial Lung Disease

NCT ID: NCT04089826

Last Updated: 2019-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-30

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study the effect of using long term oxygen therapy in patients with interstitial lung disease and chronic hypoxia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

long term oxygen can be used in patients with interstitial lung disease with hypoxia and the aim of this study is to k ow whether this will improve life style , exercise tolerance in those patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long Term Oxygen Therapy Interstitial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with ILD and hypoxia with SO2\<88 at room air and PO2 \< or equal 7.3k.pa or \< or equal 8 k.pa in presence of lower limb edema , pulmonary hypertension or polycythemia
* age group 18 : 70

Exclusion Criteria

* Causes of chronic respiratory failure other than ILD.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Asmaa Mahmoud Mohammed Eltayeb

Resident at chest department Assiut university

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Asmaa Mahmoud Mohamed Eltayeb

Role: CONTACT

01114203879

Atef Farouk Elqarn

Role: CONTACT

01006474200

References

Explore related publications, articles, or registry entries linked to this study.

Cobo-Ibanez T, Lopez-Longo FJ, Joven B, Carreira PE, Munoz-Fernandez S, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, Muriel ET, Mateos CB, de la Pena Lefebvre PG, Gomez-Gomez A, Nogal LB, Perez A, Almodovar R, Lojo L, Ruiz-Gutierrez L, Lopez-Robledillo JC, Garcia de Yebenes MJ, Nuno-Nuno L. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol. 2019 Mar;38(3):803-815. doi: 10.1007/s10067-018-4353-2. Epub 2018 Nov 3.

Reference Type BACKGROUND
PMID: 30392161 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Role of LTOT in Pateints e ILD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ambulatory Oxygen for ILD
NCT01906931 COMPLETED PHASE2
Nocturnal Oxygen Therapy
NCT00000564 COMPLETED PHASE3
Intubated ICU Patients
NCT02171091 TERMINATED